Discovery of VEGFR inhibitors through virtual screening and energy assessment
© 2023 Wiley Periodicals LLC..
Vascular endothelial growth factor receptor-2 (VEGFR-2) is crucial in promoting tumor angiogenesis and cancer metastasis. Thus, inhibition of VEGFR-2 has appeared as a good tactic for cancer treatment. To find out novel VEGFR-2 inhibitors, first, the PDB structure of VEGFR-2, 6GQO, was selected based on atomic nonlocal environment assessment (ANOLEA) and PROCHECK assessment. 6GQO was then further used for structure-based virtual screening (SBVS) of different molecular databases, including US-FDA approved drugs, US-FDA withdrawn drugs, may bridge, MDPI, and Specs databases using Glide. Based on SBVS, receptor fit, drug-like filters, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of 427877 compounds, the best 22 hits were selected. From the 22 hits, hit 5 complex with 6GQO was put through molecular mechanics/generalized born surface area (MM/GBSA) study and hERG binding. The MM/GBSA study revealed that hit 5 possesses lesser binding free energy with more inferior stability in the receptor pocket than the reference compound. The VEGFR-2 inhibition assay of hit 5 disclosed an IC50 of 165.23 nM against VEGFR-2, which can be possibly enhanced through structural modifications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of biochemical and molecular toxicology - 37(2023), 5 vom: 24. Mai, Seite e23321 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reang, Jurnal [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADMET analysis |
|---|
| Anmerkungen: |
Date Completed 15.05.2023 Date Revised 15.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jbt.23321 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353151521 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353151521 | ||
| 003 | DE-627 | ||
| 005 | 20231226055342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jbt.23321 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1177.xml |
| 035 | |a (DE-627)NLM353151521 | ||
| 035 | |a (NLM)36808794 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reang, Jurnal |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Discovery of VEGFR inhibitors through virtual screening and energy assessment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.05.2023 | ||
| 500 | |a Date Revised 15.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Vascular endothelial growth factor receptor-2 (VEGFR-2) is crucial in promoting tumor angiogenesis and cancer metastasis. Thus, inhibition of VEGFR-2 has appeared as a good tactic for cancer treatment. To find out novel VEGFR-2 inhibitors, first, the PDB structure of VEGFR-2, 6GQO, was selected based on atomic nonlocal environment assessment (ANOLEA) and PROCHECK assessment. 6GQO was then further used for structure-based virtual screening (SBVS) of different molecular databases, including US-FDA approved drugs, US-FDA withdrawn drugs, may bridge, MDPI, and Specs databases using Glide. Based on SBVS, receptor fit, drug-like filters, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of 427877 compounds, the best 22 hits were selected. From the 22 hits, hit 5 complex with 6GQO was put through molecular mechanics/generalized born surface area (MM/GBSA) study and hERG binding. The MM/GBSA study revealed that hit 5 possesses lesser binding free energy with more inferior stability in the receptor pocket than the reference compound. The VEGFR-2 inhibition assay of hit 5 disclosed an IC50 of 165.23 nM against VEGFR-2, which can be possibly enhanced through structural modifications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADMET analysis | |
| 650 | 4 | |a VEGFR-2 | |
| 650 | 4 | |a molecular modeling | |
| 650 | 4 | |a structure-based virtual screening | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor Receptor-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Sharma, Kalicharan |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Prabodh C |e verfasserin |4 aut | |
| 700 | 1 | |a Yadav, Vivek |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Vinita |e verfasserin |4 aut | |
| 700 | 1 | |a Majeed, Jaseela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biochemical and molecular toxicology |d 1998 |g 37(2023), 5 vom: 24. Mai, Seite e23321 |w (DE-627)NLM093581521 |x 1099-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:5 |g day:24 |g month:05 |g pages:e23321 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jbt.23321 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 5 |b 24 |c 05 |h e23321 | ||